MEETINGS - Euromedlab 2001 (Czech Republic) May - June 2001:
This article was originally published in Clinica
Euromedlab 2001, the 14th IFCC-FESCC European congress of clinical chemistry and laboratory medicine, will be held at the Prague Congress Centre, Czech Republic, on May 26-June 1. For more information contact the Euromedlab secretariat. Tel: +420 49 583 3040. Fax: +420 49 583 2003. Email: firstname.lastname@example.org
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.